OTCM
BVNXF
Market cap136mUSD
Jul 23, Last price
14.71
Name
Bioventix PLC
Chart & performance
P/E
—
P/S
—
EPS
1.45
Vol. 1Y
—
Shs. 5Y
0.27%
Rev. 5Y
4.92%
Div Yld LY
—
Div Yld TTM
—
Revenues
13m
-3.61%
Net income
8m
-6.33%
CFO
7m
-15.73%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Key people
Bruce Hiscock
Chief Financial Officer, Executive Director · since 2020
Peter Harrison
Chief Executive Officer, Executive Director
Independent Non-Executive Chairman of the Board · since 2004
Joanne Pisani
Non-Executive Independent Director · since 2023
Legal address
27-28 EASTCASTLE STREET
LONDON, LND W1W 8DH
GB
LONDON, LND W1W 8DH
GB
Headquarters
7 ROMANS BUSINESS PARK
EAST STREET
FARNHAM, SRY GU9 7SX
GB
EAST STREET
FARNHAM, SRY GU9 7SX
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||